In collaboration with

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by an educational grant from Regeneron

TITLE: Emerging Biologic Strategies for CRSwNP - Harnessing the Power of a Social Peer-based Learning Environment to Optimize Outcomes for Patients with Chronic Rhinosinusitis with Nasal Polyps

Release | Expiration: December 31, 2025 – August 21, 2026
 

STATEMENT OF NEED
Despite recent advances, several challenges continue to limit optimal use of biologics in CRSwNP. ENTs and allergists may underrecognize key clinical, inflammatory, and comorbid features that help identify candidates for biologic therapy and predict recurrence risk. Uncertainty persists around when to initiate biologics in relation to endoscopic sinus surgery, with limited guidance on whether they should be used before, after, or in place of surgery. The absence of U.S. specific position statements further contributes to variability in identifying which patients are appropriate candidates for biologics, determining the optimal timing of biologic initiation related to FESS, and selecting the best agent based on clinical and inflammatory profiles. In addition, poor communication between ENT and allergy teams often results in fragmented care, delayed decisions, and inconsistent treatment approaches.

Given the growing complexity of CRSwNP management, it is critical to connect expert faculty with practicing ENTs and allergists who may be less familiar with the evolving role of biologics. The proposed curriculum offers expert-led, small-group learning designed to facilitate collaborative discussions on biologic selection, surgical timing, and coordinated care. With several biologics approved in recent years, new agents on the horizon, and anticipated U.S. guidance forthcoming, this program is exceptionally well-timed, coinciding with these developments, and offering ENTs and allergists a unique opportunity to learn about, discuss, reflect on, and apply new guidance and align real-world practice with the evolving treatment landscape.
 

EDUCATIONAL OBJECTIVES

UTILIZE clinical and inflammatory features that guide biologic selection and signal recurrence risk in CRSwNP

DETERMINE how and when to incorporate biologics into CRSwNP management and sequencing treatment before, after, or in place of FESS

IMPLEMENT treatment strategies that incorporate biologics as add-on maintenance therapy for type 2 inflammation in CRSwNP, based on emerging guidance

STRENGTHEN cross-specialty collaboration between ENTs and allergists to ensure timely, coordinated care and appropriate integration of biologic therapies in CRSwNP
 

TARGET AUDIENCE
ENT’s and Allergy Clinicians (MDs and APPs)

FACULTY

	Cecelia Damask, DO, FAOCOHNS, FAAOA AdventHealth[CT1]  - Orlando ENT & Allergy Assistant Professor – Department of Otolaryngology University of Central Florida Orlando, FL
Disclosures	TBD

	Anju T. Peters, MD, MSCI Professor of Medicine Associate Chief of Clinical Research and Practice Innovation Division of Allergy and Immunology  Director, Center for Clinical Research Northwestern University Clinical and Translational Sciences Institute (NUCATS) Medical Director, Northwestern Medicine Clinical Research Unit Chicago, IL
Disclosures	TBD

TECHNICAL WRITER
Erika K. Lunz, PharmD

Disclosures
No relevant financial disclosures

PEER REVIEWER
Leonard Bacharier, MD

Disclosures
No relevant financial disclosures
 

ACCREDITED PROVIDER DISCLOSURE
None of the planners, reviewers, and AAAAI and RealCME staff for this educational activity have relevant financial relationship(s) with ineligible companies to disclose.
 

DISCLOSURE OF FINANCIAL RELATIONSHIPS POLICY
AAAAI adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME/CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.


ACCREDITED PROVIDER & ACCREDITATION STATEMENTS
This activity is accredited through AAAAI. 

CME: The American Academy of Allergy Asthma and Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CE: The American Academy of Allergy Asthma and Immunology (AAAAI) is a Provider approved by the California Board of Registered Nursing, Provider #10704.

CREDIT DESIGNATION STATEMENT
The AAAAI designates this activity for up to 4.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


DISCLOSURE OF UNLABELED USE
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a clinician relative to diagnostic and treatment options for a specific patient's medical condition.

Disclaimer
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AAAAI and RealCME. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

If you have any questions relating to the accreditation of this activity, please contact cme@aaaai.org


METHOD OF PARTICIPATION/INSTRUCTIONS
Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-assessment and evaluation, and have received a digital copy of your credit certificate.

In order to claim the maximum amount of credit available, you must complete all of the following:

• Baseline/Final Assessments: 30 minutes each for a total of up to 1.00 hour of CME
• Three (3) Self-Study Modules: 15 minutes each for a total of up to 0.75 hour of CME
• Two (2) Live Group Discussion: 45 minutes each for a total of up to 1.50 hour of CME
• Two (2) Group Challenges: 30 minutes each for a total of up to 1.00 hour of CME
• Action Plan (1) development: 30 minutes for a total of 0.50 hour of CME
   

PRIVACY STATEMENT
The American Academy of Allergy, Asthma & Immunology (AAAAI) takes your privacy seriously. AAAAI will only use your personal information to administer your registration, attendance, and credit claiming/attendance record for this activity, to provide services that you have requested from AAAAI and otherwise as you may expressly consent. A complete copy of AAAAI’s Legal and Privacy Notices, the terms of which are incorporated herein, can be found here.

By providing consent, you are allowing AAAAI to process your personal data. AAAAI will collect and store information you provide in the Registration Forms for the purposes of enabling us to register your attendance at the activity; to assist with administrative, planning and marketing purposes; and to allow the compilation and analysis of statistics relevant to AAAAI. 
 
The information you provide in the Registration Forms, and information provided at any other time during this activity, including without limitation any feedback obtained during the activity, will be used by AAAAI to offer, provide and continue to improve its educational activities and other services. The AAAAI may also use your email address to communicate important information regarding this activity and for marketing purposes for future activities. AAAAI will not otherwise, without your consent, use or disclose your personal information for any purpose unless it would reasonably be expected that such a purpose is related to the offer, provision and improvement of the activity or where such purpose is permitted or required by law. 

I understand that it is my right to withhold consent to the above Privacy and Data Protection Notice, or to withdraw my previous consent at any time. I further understand that without my consent, it is not possible to process my registration/housing request for this activity. Please contact the AAAAI Education Team at (414) 272-6071 if you have any further questions about how this will affect your registration request for this activity.